The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Ascendis Pharma A/S SPONSORED ADS 04351P101 12,428 133,691 SH   SOLE   133,691 0 0
Cymabay Therapeutics, Inc. COM 23257D103 4,843 1,641,804 SH   SOLE   1,641,804 0 0
Natera, Inc. COM 632307104 5,641 159,160 SH   SOLE   159,160 0 0
Verona Pharma PLC. SPONSORED ADS 925050106 4,656 1,111,112 SH   SOLE   1,111,112 0 0